Cranebio

Crane Bio develops rapid genetic test kits that provide on-the-spot results without the need for special equipment. These kits are versatile, serving applications in infectious disease screening, water quality inspection, and food sanitation. The company also focuses on wearable testing kits for female healthcare, emphasizing ease of use to promote routine self-testing and early disease detection. Crane Bio operates in the healthcare and biotechnology markets, targeting consumers who require convenient and reliable self-testing solutions. The business model revolves around the sale of these test kits, generating revenue through direct consumer sales and partnerships with healthcare providers. By leveraging DNA origami technology, Crane Bio has created artificial enzymes called Dozyme, which activate only in the presence of specific substrates, allowing for highly sensitive and specific medical testing. This innovation is particularly useful for detecting various viruses and bacteria, including COVID-19.

Keywords: genetic test kits, infectious disease, water quality, food sanitation, wearable testing, female healthcare, self-testing, DNA origami, artificial enzymes, COVID-19 detection.